AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37209893
Drug: Intrauterine balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrauterine balloon tamponade after sulprostone infusion
Trial: 37209996
Drug: Drug Coated
RxNorm normalized name: Drug coated stent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Coated Balloons (DCBs)
Trial: 37210048
Drug: 5-fraction Stereotactic
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fraction Stereotactic MR-guided on-table Adaptive Radiation Therapy (SMART), 50 gray in 5 fractions.
Trial: 37210098
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg rimegepant
Trial: 37210099
Drug: Valbenazine (≤80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valbenazine (≤80 mg, as tolerated)
Trial: 37210308
Drug: mRNA-1388 25
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1388 25 μg
Trial: 37210308
Drug: mRNA-1388 50
RxNorm normalized name: mRNA-3705
DrugBank: mRNA-3705 (DB17668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1388 50 μg
Trial: 37210308
Drug: mRNA-1388 100
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1388 100 μg
Trial: 37210308
Drug: mRNA-1388 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1388 (all doses)
Trial: 37210308
Drug: mRNA-1388 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1388 (50 μg and 100 μg)
Trial: 37210741
Drug: 1 dose
RxNorm normalized name: Ribose 3 GM/1 DOSE Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of 5-µg rS with 50 µg Matrix-M adjuvant
Trial: 37210741
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of 5-µg rS with 50 µg Matrix-M adjuvant
Trial: 37210741
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of 25-µg rS with 50 µg Matrix-M adjuvant
Trial: 37210742
Drug: Metolazone 5-10
RxNorm normalized name: metolazone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metolazone 5-10 mg once daily
Trial: 37210887
Drug: Cognitive Therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Therapy plus a Memory Support Intervention
Trial: 37210887
Drug: Cognitive Therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Therapy as usual
Trial: 37211246
Drug: Ziltivekimab 15
RxNorm normalized name: Ziltivekimab
DrugBank: Ziltivekimab (DB18836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziltivekimab 15 mg and 30 mg
Trial: 37211611
Drug: Home-based multicomponent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based multicomponent exercise program with weekly telephone supervision from diagnosis until three months post-surgery
Trial: 37212315
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three treatment arms (AVT04, US-RP, EU-RP)
Trial: 37212651
Drug: Sertraline (25-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (25-100 mg)
Trial: 37212686
Drug: Sintilimab plus
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab plus S-1 combined intraperitoneal and intravenous paclitaxel
Trial: 37212970
Drug: Heavy lifting
RxNorm normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heavy lifting strength training (HLST) program, 12 weeks, twice weekly, lifting 80-90% of 1 repetition maximum (1RM)
Trial: 37213102
Drug: Danuglipron 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danuglipron 120 mg twice daily
Trial: 37213102
Drug: Danuglipron 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danuglipron 80 mg twice daily
Trial: 37213122
Drug: Dual thrombolytic
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual thrombolytic treatment with 5 mg intravenous alteplase and 40 mg intravenous mutant prourokinase
Trial: 37213122
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care with 0.9 mg/kg intravenous alteplase
Trial: 37213907
Drug: Electromagnetic Network
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electromagnetic Network Targeting Field (ENTF) therapy
Trial: 37214210
Drug: MALT1 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MALT1 inhibitor
Trial: 37214431
Drug: Exogenous DL-beta-hydroxybutyrate
RxNorm normalized name: beta-phenyl-DL-phenylalanine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous DL-beta-hydroxybutyrate supplementation, dosage and duration not specified.
Trial: 37214450
Drug: vonoprazan-containing triple
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: vonoprazan-containing triple therapy
Trial: 37214890
Drug: Strengths-based and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strengths-based and community-driven intervention to reduce gun violence, details on dosage and duration not available.
Trial: 37215389
Drug: Low-dose prucalopride
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prucalopride (0.04 mg/kg)
Trial: 37215389
Drug: High-dose prucalopride
RxNorm normalized name: prucalopride
DrugBank: Prucalopride (DB06480)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: High-dose prucalopride (0.08 mg/kg)
Trial: 37215679
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU), supportive counseling and psychoeducation
Trial: 37216357
Drug: Short-term antibiotic
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term antibiotic treatment (8 weeks in early IOM and 12 weeks in delayed IOM)
Trial: 37216357
Drug: Long-term antibiotic
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term antibiotic treatment (12 weeks in early IOM or until fracture healing or implant removal in delayed IOM)
Trial: 37216357
Drug: Both short-term
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both short-term and long-term treatments
Trial: 37216396
Drug: Vemurafenib (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vemurafenib (20 mg/kg) combined with Ara-C (100 mg/m2 every 12 h, days 1-5) and 2-CdA (6 mg/m2 per day, days 1-5) followed by mono 2-CdA.
Trial: 37216921
Drug: Crinecerfont (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crinecerfont (50 mg twice daily for 14 days)
Trial: 37217183
Drug: Dimethyl fumarate
RxNorm normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dimethyl fumarate (DMF) therapy
Trial: 37217243
Drug: IDO/PD-L1 targeting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IDO/PD-L1 targeting peptide vaccine combined with nivolumab (NCT03047928)
Trial: 37217243
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (patients in cohort B receiving anti-PD-1 therapy with peptide vaccine)
Trial: 37217273
Drug: TAS5315 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS5315 4 or 2 mg once daily for 12 weeks
Trial: 37217882
Drug: Driving pressure-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Driving pressure-guided ventilation (titration group)
Trial: 37217911
Drug: Implant insertion
RxNorm normalized name: Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant insertion with internal connection implants (Twinfit, Dentaurum, Ispringen, Germany) after piezoelectric implant site preparation.
Trial: 37218946
Drug: High-dose radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose radiation therapy guided by pre-RT Cho/NAA twice normal volume (Cho/NAA ≥ 2x)
Trial: 37219686
Drug: Tovorafenib administered
RxNorm normalized name: Tovorafenib
DrugBank: Tovorafenib (DB15266)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tovorafenib administered once every other day (Q2D) at RP2D of 200 mg
Trial: 37219686
Drug: Tovorafenib administered
RxNorm normalized name: Tovorafenib
DrugBank: Tovorafenib (DB15266)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tovorafenib administered once weekly (QW) at RP2D of 600 mg
Trial: 37219865
Drug: Clenbuterol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clenbuterol (40 μg daily increased to 80 μg twice daily)
Trial: 37220015
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment model (baseline population testing with ART by country standard)
Trial: 37220119
Drug: Fortetropin® supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortetropin® supplement (FOR-SUPP, n = 12) consuming 19.8 g/d of FOR
Trial: 37220130
Drug: Endovenous laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovenous laser ablation (EVLA) of the incompetent saphenous trunk without tributary treatment
Trial: 37220815
Drug: Post-treatment CST
RxNorm normalized name: dimethiconol (50000 CST)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-treatment CST close to estimated inflection points (217 to 256 μm)
Trial: 37220822
Drug: Study medications
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study medications delivery
Trial: 37220998
Drug: Tirofiban combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirofiban combined with Aspirin
Trial: 37220998
Drug: Placebo combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo combined with Aspirin
Trial: 37221177
Drug: Low bolus
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low bolus + low infusion (15 mg + 0.6 mg/min)
Trial: 37221177
Drug: High bolus
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High bolus + high infusion (25 mg + 1 mg/min)
Trial: 37221177
Drug: Low infusion
RxNorm normalized name: Solution, Multi Ingredient Topical application Solution [AVEENO POSITIVELY RADIANT MAXGLOW INFUSION DROPS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low infusion (0.6 mg/min)
Trial: 37221177
Drug: High infusion
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High infusion (1 mg/min)
Trial: 37221407
Drug: In-hospital pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-hospital pharmacotherapy optimization
Trial: 37221466
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated DENV3 monovalent vaccine rDEN3Δ30/31-7164
Trial: 37222204
Drug: Nivolumab as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab as adjuvant treatment after curative surgery for oesophagal or gastroesophageal junction cancer
Trial: 37222204
Drug: Neoadjuvant immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant immunotherapy in dMMR colorectal cancers
Trial: 37222252
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide mononitrate (40-60 mg/d)
Trial: 37222252
Drug: Combination ISMN-cilostazol
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination ISMN-cilostazol (40-60 mg/d and 200 mg/d, respectively)
Trial: 37222252
Drug: No study
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No study drug (control group)
Trial: 37223439
Drug: AXA1125 (33.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AXA1125 (33.9 g, administered orally in a liquid suspension twice daily for four weeks)
Trial: 37223439
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching placebo administered orally in a liquid suspension twice daily for four weeks)
Trial: 37223507
Drug: Low-dose human
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose human umbilical cord-derived mesenchymal stem cells (hUC-MSCs)
Trial: 37223666
Drug: Rivaroxaban 10
RxNorm normalized name: rivaroxaban 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 10 mg OD for 14 days
Trial: 37223981
Drug: Autonomic Modulation
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Autonomic Modulation Training (AMT) intervention, which includes 1 session of baseline survey measures, 6 weekly sessions of HRV biofeedback training, and 1 follow-up session.
Trial: 37224065
Drug: Lidocaine and
RxNorm normalized name: Lidocaine and Tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine and Ketamine combination
Trial: 37224228
Drug: L19TNF in
RxNorm normalized name: Daromun component l19tnf
DrugBank: Onfekafusp alfa (DB16269)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L19TNF in combination with CCNU
Trial: 37224232
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg over 40 minutes, twice per week)
Trial: 37224883
Drug: Dual Pathway
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual Pathway Inhibition (DPI) with Aspirin plus Vascular-Dose Rivaroxaban
Trial: 37224883
Drug: Dual Antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual Antiplatelet Therapy (DAPT) with Aspirin (81 mg/qd) plus a P2Y12 inhibitor
Trial: 37225045
Drug: sacubitril/valsartan treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sacubitril/valsartan treatment
Trial: 37225248
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (discussion about medication)
Trial: 37225265
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1000 mg two times a day for 14 days)
Trial: 37225266
Drug: Dry needling
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dry needling (DN) - ultrasound-guided intramuscular and interfascial DN 8-10 times per pain point or until local twitch responses are no longer elicited, with 30 minutes of indwelling.
Trial: 37225266
Drug: Pulsed radiofrequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed radiofrequency (PRF) - ultrasound-guided intramuscular (0.9% saline 2 mL, 42℃, 2 Hz, 2 min) and interfascial (0.9% saline 5 mL, 42℃, 2 Hz, 2 min) PRF.
Trial: 37225267
Drug: Sociodemographic information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sociodemographic information and satisfaction with treatment data collection
Trial: 37225552
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapy with 20 fractions of radiotherapy
Trial: 37225552
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapy with 32 fractions of radiotherapy
Trial: 37225552
Drug: Concomitant therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapies in both 20 and 32 fractions of radiotherapy
Trial: 37225710
Drug: Closed-loop neuromodulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop neuromodulation treatment
Trial: 37226141
Drug: CHAMPS intervention
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CHAMPS intervention (CleverCap pill bottle synced to WiseApp)
Trial: 37226208
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose frequency (4 times per week for 6 weeks)
Trial: 37226208
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose frequency (2 times per week for 12 weeks)
Trial: 37226210
Drug: PMHC-treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PMHC-treatment
Trial: 37226281
Drug: Complete Vocal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete Vocal Technique voice therapy (CVT-VT)
Trial: 37226519
Drug: CTPS1 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CTPS1 inhibitor (STP938)
Trial: 37227176
Drug: SYNB1891 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYNB1891 monotherapy
Trial: 37227176
Drug: SYNB1891 in
RxNorm normalized name: SYNB1891
DrugBank: SYNB1891 (DB17541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYNB1891 in combination with atezolizumab
Trial: 37227726
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of oral rivaroxaban for 7 days (short prophylaxis)
Trial: 37227726
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of oral rivaroxaban for 28 days (long prophylaxis)
Trial: 37227726
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of oral rivaroxaban for both 7 and 28 days
Trial: 37227734
Drug: Intraperitoneal olvimulogene
RxNorm normalized name: Olvimulogene nanivacirepvec
DrugBank: Olvimulogene nanivacirepvec (DB16268)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal olvimulogene nanivacirepvec (Olvi-Vec) followed by platinum-doublet chemotherapy with or without bevacizumab
Trial: 37227729
Drug: P2Y12 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: P2Y12 inhibitor (Ticagrelor or Clopidogrel)
Trial: 37227729
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (no P2Y12 inhibitor)
Trial: 37227729
Drug: P2Y12 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: P2Y12 inhibitor
Trial: 37227937
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg administered before dialysis session initiation in kidney failure group.
Trial: 37228142
Drug: Multifaceted environmental
RxNorm normalized name: ZINC OXIDE 225 mg in 100 mL TOPICAL CREAM [ENVIRONMENTAL DEFENSE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifaceted environmental control intervention (dynamic light therapy, auditory masking, rationalization of ICU nocturnal patient care activities)
Trial: 37229650
Drug: Baricitinib (BARI)
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Baricitinib (BARI) 4 mg/day for 52 weeks
Trial: 37229775
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg of elemental oral iron (18.6 mg ferrous sulphate) twice daily for 8 weeks
Trial: 37229879
Drug: Carboplatin dosing
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin dosing based on Jelliffe formula
Trial: 37229879
Drug: Carboplatin dosing
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin dosing based on MDRD and Cockcroft-Gault formulas
Trial: 37230101
Drug: Supplemental dolutegravir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental dolutegravir (50 mg 12 h later)
Trial: 37230366
Drug: Continuous upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Continuous upadacitinib 30 mg
Trial: 37230366
Drug: Switching from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching from dupilumab to upadacitinib 30 mg
Trial: 37230524
Drug: One oral
RxNorm normalized name: Geone Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One oral loading dose of 100,000 IU vitamin D
Trial: 37231080
Drug: Mescaline 500
RxNorm normalized name: Mescaline
DrugBank: Mescaline (DB19083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mescaline 500 mg
Trial: 37231080
Drug: Psilocybin 20
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin 20 mg
Trial: 37231080
Drug: Mescaline 300
RxNorm normalized name: Mescaline
DrugBank: Mescaline (DB19083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mescaline 300 mg
Trial: 37231350
Drug: Lu AG09222
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lu AG09222 + PACAP38 infusion
Trial: 37231350
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + PACAP38 infusion
Trial: 37231477
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (oral information and brochures)
Trial: 37231479
Drug: Pre-release extended-release
RxNorm normalized name: ascorbic acid / folic acid Extended Release Oral Tablet [Pre Folic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-release extended-release naltrexone (XR-NTX) + referral to community XR-NTX